Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
127
resultados
Última actualización
14/03/2026 [06:56:00]
Resumen de: US20260069765A1
An infusion system is disclosed comprising: a device for delivering insulin into tissue of a user; and a cartridge assembly including an integrated infusion catheter and CGM sensor subassembly and an introducer needle for introducing the integrated infusion catheter and CGM sensor subassembly into the tissue of the user, wherein the cartridge assembly configured to move from (a) first position, wherein the integrated infusion catheter and CGM sensor subassembly is in a first position above the tissue of the user to (b) a second position, wherein the integrated infusion catheter and CGM sensor subassembly is in a deployed position inserted into tissue of the user.
Resumen de: US20260069173A1
Various examples are directed to a glucose sensor comprising a working electrode to support an oxidation reaction and a reference electrode to support a redox reaction. The reference electrode may comprise silver and silver chloride. The Glucose sensor may also comprise an anti-mineralization agent positioned at the reference electrode to reduce formation of calcium carbonate at the reference electrode.
Resumen de: US20260069781A1
The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.
Resumen de: US20260069778A1
The invention discloses an automatic detection method based on the change rate of the difference between the actual blood glucose values, including: obtaining an actual blood glucose value of the user at the current time; obtaining a historical actual blood glucose value of the user at the previous time, and calculate a difference between the actual blood glucose values at the current time and at the previous time; calculating a change rate of the difference between the actual blood glucose values at the current time; and comparing the change rate of the difference between the actual blood glucose values at the current time with a preset threshold, and determining an event type based on the comparing result. Based on the determined event type, the artificial pancreas can automatically adjust the corresponding infusion strategy to achieve closed-loop control of the artificial pancreas.
Resumen de: US20260069780A1
Techniques disclosed herein related to controlling insulin delivery. In some embodiments, the techniques may involve delivering insulin via an insulin infusion device according to a closed-loop mode of delivery. The techniques may further involve determining, at a first time point, insulin delivery is to be switched from the closed-loop mode of delivery to a second mode of delivery. The techniques may further involve switching operation of the insulin infusion device to the second mode of delivery such that insulin is delivered via the insulin infusion device according to the second mode of delivery.
Resumen de: US20260069779A1
Provided is a wearable medical device that includes a processor or logic circuitry. The wearable medical device may include a memory storing instructions that, when executed by the processor or logic circuitry, configure the wearable medical device to determine, by the processor or the logic circuitry, that an event affecting a blood glucose measurement value trend of a user has occurred. Based on the occurrence of the event, the processor or the logic circuitry may select a mode of operation of the analyte sensor, and generate a signal indicating the selected mode of operation. The mode of operation may correspond to a sampling frequency of a physical attribute or physiological condition of a user of the wearable medical device.
Resumen de: US20260069776A1
Provided are a method, apparatus, and computer program for providing a notification according to a period of use of a drug infusion device. A time point at which the drug infusion device switches from an inactive mode to an active mode may be determined as a use start time point. Also, an impending expiration notification indicating that expiration of a period of use of the drug infusion device is imminent may be provided at a first time point after a certain period from the use start time point, based on a usable period and a user set time of the drug infusion device. In addition, an expiration notification indicating that the period of use of the drug infusion device has expired may be provided at a second time point after the usable period from the use start time point.
Resumen de: US20260069218A1
Disclosed is a management device for displaying glucose information. The screen of the management device is divided into the plurality of display areas, at least comprising a first display area for displaying the status of the management device, a second display area for displaying real-time glucose information, and a third display area for displaying historical glucose concentration information. The user can intuitively and easily get the glucose information in the body.
Resumen de: EP4706531A2
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Resumen de: EP4706532A2
The present disclosure relates to a continuous blood glucose measurement body attachment unit, and provides a continuous blood glucose measurement body attachment unit, which is manufactured in an assembled state in an applicator so as to minimize separate additional operations, such that the body attachment unit can be attached to the body with only a simple operation of the applicator and, particularly, the body attachment unit has a wireless communication chip so as to be capable of communicating with an external terminal, thereby enabling simple and convenient usage without an additional operation in which a separate transmitter must be connected and enabling maintenance to be more easily performed, and after the body attachment unit is attached to the body, an operation starts by the control of a user, such that an operation start time point can be adjusted to an appropriate time point according to the needs of the user, and an operation can start in a stabilized state, such that blood glucose can be more accurately measured.
Resumen de: EP4706533A2
The present disclosure relates to a continuous glucose monitoring device, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work for a user in attaching the body attachment unit to a body, and allowing attachment of the body attachment unit to the body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, the continuous glucose monitoring device is activated by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and the continuous glucose monitoring device can be activated in a stabilized state, and thereby can monitor blood glucose more accurately.
Resumen de: EP4706530A2
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Resumen de: EP4706516A1
An embodiment may provide a blood glucose measurement method using a learning model, the method including obtaining a biosignal, generating biometric data from the biosignal, training a learning model with training biometric data, so as to output a blood glucose value, obtaining a blood glucose value corresponding to the biometric data from the biometric data via the learning model when training is completed, and providing, to a user, the blood glucose value corresponding to the biometric data.
Resumen de: WO2024229007A2
Embodiments relate to systems and methods for developing and implementing a model. Developing the model can involve receiving an insulin dosing rule (IDR) including plural metabolic states (Xs) and corresponding insulin dosage recommendations (Us), generating a saturated data set with the plural Xs and corresponding Us so that the saturated data set has optimal data density, generating a saturated look-up table (STL) with the saturated data set, and encoding the STL into a neural network. Implementing the model can involve receiving a measurement indicative of a metabolic state (Xm), implementing a model a SLT encoded into a neural network, the SLT including a saturated data set of optimal data density, wherein implementation of the model applies the Xm to the SLT to identify a corresponding U, and monitoring, analyzing, or influencing a concentration of glucose levels in a fluid using the identified U.
Resumen de: EP4678094A2
The present disclosure relates to a continuous blood sugar measuring sensor member, wherein: since an electrode layer formed on one surface of a substrate is connected to a sensor contact point part on the other surface of the substrate through a via hole and thus two electrode layers may be formed on different opposite surfaces without having to be formed on the same surface of the substrate, the width of the substrate may be further reduced and an overall minimized and simplified structure may be ensured; since an electrode connection layer formed at the via hole is not formed in a shape of filling the via hole but is formed only on the inner circumferential surface, a filling defect occurring in a process of filling the via hole and a fault in electrical connection according thereto may be prevented and thus a more stable structure may be ensured; and since a plurality of via holes are formed, despite damage to or the occurrence of a defect in an electrode connection layer formed at one of the via holes, electrical connection is maintained by electrode connection layers formed at the remaining via holes, and thus more stable performance may be maintained.
Resumen de: US20260061122A1
A device in accordance with an embodiment of the present technology includes a port through which the device receives and dispenses infusion liquid (e.g., insulin solution) and a container that holds the infusion liquid. The device also includes a hub at a flowpath extending between the port and the container. The hub defines a first passage and a second passage in parallel with one another. The device further includes a conditioner and a check valve at the first and second passages, respectively. The conditioner conditions liquid moving between the container and the port by passing the liquid through an adsorbent filter and a mechanical filter. The check valve causes liquid moving between the port and the container to move preferentially via the first passage when flowing in one direction and to move preferentially via the second passage when flowing in an opposite direction.
Resumen de: US20260061128A1
Techniques disclosed herein relate to safe correction boluses. In some embodiments, the techniques involve obtaining a plurality of sensor glucose readings for a patient. The techniques may further involve determining, based on the plurality of sensor glucose readings that the patient has consumed a meal. The techniques may further involve in response to determining the patient has consumed the meal, reducing a hypoglycemia threshold from a first value to a second value lower than the first value. The techniques may further involve determining a correction bolus dosage based on the reduced hypoglycemia threshold.
Resumen de: US20260061129A1
Exemplary embodiments may enable a user to schedule medicament bolus deliveries, such as insulin boluses, for future dates and times. The exemplary embodiments may provide the ability to delay a scheduled medicament bolus delivery by short periods of time. The user may reschedule a scheduled medicament bolus delivery by entering a new date and/or time for the medicament bolus delivery. Still further, a user may cancel a scheduled medicament bolus delivery. In addition, exemplary embodiments may enable multiple medicament bolus deliveries to be viewed and managed.
Resumen de: US20260066121A1
An embodiment may provide a blood glucose measurement method using a learning model, the method including obtaining a biosignal, generating biometric data from the biosignal, training a learning model with training biometric data, so as to output a blood glucose value, obtaining a blood glucose value corresponding to the biometric data from the biometric data via the learning model when training is completed, and providing, to a user, the blood glucose value corresponding to the biometric data.
Resumen de: US20260066125A1
Provided are devices and systems for determining a blood glucose level for a subject, the device comprising a processor and a memory in communication with the processor, the device comprising: a receiving unit for obtaining a voice sample from the subject; an extraction unit for extracting at least one voice biomarker feature value from the voice sample for at least one predetermined voice biomarker feature; a determining unit for determining the blood glucose level for the subject based on the at least one voice biomarker feature value and a blood glucose level prediction model; and an output unit for outputting the blood glucose level or an output based on the blood glucose level for the subject.
Resumen de: WO2026047021A1
The present invention relates to lipid emulsions for parenteral administration comprising an oil phase and a pharmaceutically acceptable form of selenium, as well as to containers comprising, in separate chambers, said emulsions and an amino acid solution for parenteral administration and/or a glucose solution for parenteral administration.
Resumen de: WO2026047019A1
The present invention relates to amino acid solutions for parenteral administration comprising amino acids and a pharmaceutically acceptable form of copper, as well as to containers comprising, in separate chambers, said amino acid solutions and a lipid emulsion for parenteral administration and/or a glucose solution for parenteral administration.
Resumen de: WO2026047017A1
The present invention relates to glucose solutions for parenteral administration comprising glucose and a pharmaceutically acceptable form of iron, as well as to containers comprising, in separate chambers, said glucose solutions and a lipid emulsion for parenteral administration and/or an amino acid solution for parenteral administration.
Resumen de: WO2026045149A1
Provided in the present disclosure are an analyte concentration data-based processing device and a related method. The processing device comprises an acquisition module and a processing module. The acquisition module is configured to receive first analyte data related to a glucose concentration and second analyte data related to a ketone body concentration obtained by continuously monitoring at least two analytes of a target subject using an analyte sensor. The processing module is configured to acquire, on the basis of the first analyte data and the second analyte data, analyte concentration data comprising glucose concentration data and ketone body concentration data, acquire, on the basis of the analyte concentration data within a time period, at least one feature set, and determine, on the basis of the at least one feature set, target information at least comprising energy information. The energy information is the relationship between estimated energy intake and energy expenditure of the target subject, where the energy intake is the energy derived from ingested carbohydrates, and the energy expenditure is the energy that is consumed. Therefore, the convenience of evaluating the relationship between carbohydrate intake and consumption can be improved.
Nº publicación: WO2026049295A1 05/03/2026
Solicitante:
SD BIOSENSOR INC [KR]
SD BIOSENSOR, INC
Resumen de: WO2026049295A1
A blood glucose management system is disclosed, comprising a user terminal configured to capture an image of food, a processor, and an information providing device configured to provide the processor with blood glucose time-series information of a user prior to ingestion of the food. The processor is configured to execute a step of generating blood glucose trend prediction information of the user after ingestion of the food, based on data related to the food captured by the user terminal and the blood glucose time-series information. The user terminal is configured to display the blood glucose trend prediction information.
BOPI
Sede Electrónica
